Active — Not RecruitingNot Applicable

Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Immunocompromised Patients With Hospital-acquired Pneumonia Requiring Mechanical Ventilation

France31 participantsStarted 2023-03-28

Plain-language summary

RESPIRE is a randomized, unblinded, controlled study to measure the impact of a strategy based on a PCR test on the adjustment of antimicrobial therapy in immunocompromised patients suspected with ventilator-associated or hospital-acquired pneumonia (VAP/HAP) requiring mechanical ventilation (MV) in Intensive Care Unit (ICU). The gold-standard microbiological diagnostic method for pneumonia in the ICU is based on culture identification and antimicrobial susceptibility testing. Results are obtained in several days after the initiation of empiric antimicrobial therapy, exposing patients to a potential inappropriate broad-spectrum antimicrobial treatment. We aim to measure the impact of a PCR-based strategy to improve the percentage of patients with VAP or HAP receiving targeted antimicrobial therapy 24 hours after diagnosis compared to standard care

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult immunocompromised patients hospitalized in ICU with suspected VAP or HAP requiring MV Exclusion Criteria: * No immunodeficiency Moribund patients (SAPS II \> 90) Pregnant women Refuse to participate to the study

What they're measuring

Increase in percentage of patients with targeted antibiotics

Timeframe: 24 hours after the initiation of empiric antimicrobial therapy

Trial details

NCT IDNCT05405491

SponsorUniversity Hospital, Lille

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-03

View on ClinicalTrials.gov More Pneumonia, Ventilator-Associated trials